Nektar(US:NKTR) Prnewswire·2025-09-18 12:45Core Insights - Nektar Therapeutics announced positive results from the REZOLVE-AD Phase 2b study of rezpegaldesleukin, demonstrating significant efficacy in treating moderate-to-severe atopic dermatitis at the 2025 EADV Congress [1][2][9] Study Results - Rezpegaldesleukin achieved statistical significance on the primary endpoint of mean improvement in Eczema Area and Severity Index (EASI) at week 16 compared to placebo, with improvements of 61% for the high dose, 58% for the middle dose, and 53% for the low dose [2][3] - Key secondary endpoints also showed significant improvements, including EASI-75 (42% for high dose, 46% for middle dose, 34% for low dose) and vIGA-AD 0/1 response rates (20% for high dose, 26% for middle dose) [3][4] - Interim data for patients who crossed over from placebo to high dose rezpegaldesleukin indicated a mean EASI reduction of 68% at crossover week 16 and 75% at crossover week 24, with EASI-75 responses of 50% and 62% respectively [8] Patient-Reported Outcomes - Significant improvements were observed in patient-reported outcomes, including a 72% reduction in Daily Life Quality Index (DLQI) for the high dose group and a 67% reduction in Atopic Dermatitis Control Tool (ADCT) [5][6] - Pain Numeric Rating Scale (Pain NRS) showed a 45% reduction for the high dose group, indicating substantial relief from pain associated with atopic dermatitis [5] Safety Profile - The safety profile over the 16-week induction period showed that 60.3% of patients in pooled drug arms experienced any treatment-emergent adverse events (TEAEs), with serious adverse events occurring in 1.6% of patients [10][11] - The most common TEAEs included drug hypersensitivity and pyrexia, with all events resolving [10][11] Study Design and Enrollment - The global Phase 2b REZOLVE-AD study randomized 393 patients across approximately 110 sites, with a significant portion (68%) enrolled in Europe [12][18] - Patients were stratified based on baseline disease severity, ensuring a robust assessment of treatment efficacy [12] Future Outlook - Nektar Therapeutics is preparing to report results for rezpegaldesleukin in patients with alopecia areata in December 2025, following the promising data from the atopic dermatitis study [9][14]